News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Topicus share price fall creates a tactical buying opportunity.
  • A 63% upside target is proposed for the stock.
  • Target timeframe is roughly 180 trading days.
  • Thesis emphasizes vertical SaaS exposure as a structural growth driver.
  • Thesis highlights a recurring revenue model.
  • Thesis also points to acquisitive growth as a value catalyst.
  • Concrete entry, stop, and target levels are provided for traders.

Latest Articles

FDA eGFR Readout Backs a Speculative Long on Vera Therapeutics

FDA eGFR Readout Backs a Speculative Long on Vera Therapeutics

Vera Therapeutics' recent regulatory win and underlying kidney function data create a buyable dip for traders willing to accept biotech execution and commercial risks. Market cap near $2.3B prices in success, but short interest, healthy liquidity and an improving technical setup make a defined-risk long trade attractive over a mid-term horizon.

Cisco After the Drop: Buy the AI-Driven Dip, Not the Fear

Cisco After the Drop: Buy the AI-Driven Dip, Not the Fear

Cisco's recent pullback looks like an overreaction. The company just raised its AI order target to $9 billion and still generates ~$11.8 billion of free cash flow annually while trading at a mid-30s P/E. This trade idea lays out an entry at $112.41 with tight risk control and a $125 target over a mid-term horizon.

Valneva After VALOR: Why the Lyme Royalty Shift Reprices the Stock

Valneva After VALOR: Why the Lyme Royalty Shift Reprices the Stock

Valneva's partnership with Pfizer and the messy VALOR readout shifted the firm's path from a potential commercial blockbuster to a royalty/milestone-oriented business. That change reduces binary clinical risk but also recasts valuation. With a market cap near $676M, recent product sales and a still-meaningful cash cushion, the shares offer an asymm…

WeRide: Tactical Long After a Convincing Q2 - Plan for a Mid-Term Bounce

WeRide: Tactical Long After a Convincing Q2 - Plan for a Mid-Term Bounce

WeRide's latest quarter surprised the market and reset expectations for commercialization pace. We like a tactical long here: the company is showing improving revenue and better-than-feared unit economics, while market sentiment remains fragile. The trade is sized for a mid-term rebound and uses tight risk controls to respect headline risk in auton…

Why External TPU Sales Could Re-Rate Alphabet - A Practical Trade Plan

Why External TPU Sales Could Re-Rate Alphabet - A Practical Trade Plan

Alphabet is already pouring capital into AI infrastructure. Turning internal TPU (Tensor Processing Unit) capacity into a commercial product flips a cost center into recurring, high-margin revenue. The balance sheet, cash flow, and Cloud momentum support a long position. Trade plan: enter $341.36, target $400.00, stop loss $320.00 on a 180-trading-…

Cirrus Logic: Undervalued Apple Supplier with Cash-Generative Growth

Cirrus Logic: Undervalued Apple Supplier with Cash-Generative Growth

Cirrus Logic (CRUS) supplies audio and mixed-signal chips to Apple and other device OEMs. At $121.38 the stock trades at ~15x earnings with $572M in free cash flow and an enterprise value of ~$5.26B. With Apple-driven device refresh catalysts and a near-oversold technical setup, a disciplined long entry offers asymmetric upside over the next 45 tra…